Clinical Trial Update: Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of cabozantinib in locally advanced or metastatic unresectable adrenocortical carcinoma has completed and results were posted in 2024-12-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2024-12-10